Constellation, Lam Research, Ruby Tuesday, TPC Group: U.S. Equity Movers

Shares of the following companies had unusual moves in U.S. trading. Stock symbols are in parentheses and prices are as of 4 p.m. in New York.

Allscripts Healthcare Solutions Inc. (MDRX) fell the most in the Russell 1000 Index, sliding 6.8 percent $20.96. The software maker was cut to “hold” from “buy” at Auriga USA LLC.

Bed Bath & Beyond Inc. (BBBY) gained 10 percent to $54.55 for the biggest rally in the Standard and Poor’s 500 Index. The home furnishings retailer forecast annual earnings of $3.38 to $3.53 a share. That compares with the average analyst projection of $3.33, Bloomberg data show.

Buckle Inc. (BKE) rose 9.9 percent to $44.55, the highest price since 1992. The teen retailer reported March sales at stores open at least one year increased 8.4 percent from a year earlier. Analysts expected a decline of 1.2 percent.

Constellation Brands Inc. (STZ) rose 6.9 percent to $21.79 for the second-biggest gain in the S&P 500. The world’s largest wine company said that, excluding some items, it expects to earn at least $1.90 a share in fiscal 2012. That beat the average estimate of $1.89 from analysts in a Bloomberg survey.

Costco Wholesale Corp. (COST) rose 3.8 percent to $77.82, the third-biggest increase in the S&P 500. The largest U.S. warehouse-club chain reported total comparable sales rose 13 percent in March, beating the 7.4 percent estimate.

Immucor Inc. (BLUD) climbed 4.7 percent, the most since Jan. 7, to $20.92. The maker of products used to screen donated blood reported third-quarter earnings of 32 cents a share, beating the average analyst projection of 26 cents a share, according to data compiled by Bloomberg.

Immunogen Inc. (IMGN) advanced 27 percent, the most since July 2003, to $11.80. The Waltham, Massachusetts-based drugmaker said that patients treated with T-DM1, which consists of the company’s DM1 cancer cell-killing agent, had a significant improvement in “progression-free survival.”

Lam Research Corp. (LRCX) had the second-biggest decline in the Russell 1000 Index, dropping 5 percent to $53.52. The maker of chip-manufacturing equipment may disappoint investors when reporting earnings for the current quarter as demand slows, Citigroup Inc. wrote in a note, in which it added the idea of selling the shares its Top Picks Live! list.

KLA-Tencor Corp. (KLAC) , another semiconductor-equipment maker, declined 4.6 percent to $44.06 for the biggest retreat in the S&P 500.

Movado Group Inc. (MOV) climbed 12 percent to $16.81, the highest price since October 2008. The watch and jewelry maker reported fourth-quarter earnings that beat analysts’ estimates and said it will resume paying dividends.

Pier 1 Imports Inc. (PIR) rose 11 percent to $11.65, the highest price since April 2006. The home-furnishings retailer reported fourth-quarter earnings of 48 cents a share, beating the average analyst estimate by 1 cent.

Ruby Tuesday Inc. (RT) slumped 18 percent, the most since December 2008, to $10.92. The casual-dining chain cut its 2011 earnings forecast to a range of 74 cents to 82 cents a share, from 76 cents to 87 cents a share. That’s below the average analyst projection of 91 cents a share.

TPC Group Inc. (TPCG) jumped 13 percent to $36.71, the highest price since 2004. The maker of petrochemical-derived products had its share-price estimate increased to $42 from $39 at Oppenheimer & Co.

WD-40 Co. (WDFC) fell 6.3 percent, the most since Jan. 11, to $40.90. The San Diego-based maker of lubricants and hand soap cut its 2011 earnings forecast to a range from $2.23 to $2.35 a share, from $2.25 to $2.40 share. The average analyst forecast was $2.31 a share, Bloomberg data show.

XenoPort Inc. (XNPT) rallied 56 percent to $9.96 for the biggest gain in the Russell 2000 Index. The drugmaker and GlaxoSmithKline Plc (GSK LN) won U.S. approval for a new treatment for restless legs syndrome after more than a year of delays.

To contact the reporter on this story: Lu Wang in New York at lwang8@bloomberg.net.

To contact the editor responsible for this story: Nick Baker at nbaker7@bloomberg.net.

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.